Current Report Filing (8-k)
April 12 2017 - 9:26AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): April 11,
2017
AZURRX BIOPHARMA, INC.
|
|
|
Delaware
|
001-37853
|
46-4993860
|
(State
or Other Jurisdiction of
Incorporation
or Organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
|
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, New York
|
11226
|
(Address
of principal executive
offices)
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(646) 699-7855
(Name,
address, including zip code, and telephone number, including area
code, of agent for service of process)
NOT
APPLICABLE
(Former
Name or Former Address, if Changes Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
On
April 11, 2017, the Company issued a press release providing an
update on its ongoing open-label Phase IIa trial of lead candidate
MS1819 for the treatment of exocrine pancreatic insufficiency
associated with chronic pancreatitis. A copy of the press release
is attached to this Current Report on Form 8-K as Exhibit
99.1.
Item
9.01
Financial
Statements and Exhibits
See
Exhibit Index.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AzurRx BioPharma,
Inc
.
|
|
Date:
April 12, 2017
|
|
|
|
|
By:
|
/s/
Johan
M. Spoor
|
|
|
|
Name: Johan M. Spoor
|
|
|
|
Title: Chief Executive Officer
|
|
Exhibit Index
Exhibit No.
|
|
Description
|
|
|
|
|
|
Press
Release dated April 11, 2017
|
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Sep 2023 to Sep 2024